1-10 of 10
George E. Peoples
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Available to Purchase
G. Travis Clifton, Diane Hale, Timothy J. Vreeland, Annelies T. Hickerson, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne V. Philips, Jason J. Lukas, Jarrod P. Holmes, George E. Peoples, Elizabeth A. Mittendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2515–2523.
https://doi.org/10.1158/1078-0432.CCR-19-2741
Published: 01 June 2020
View articletitled, Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Open the PDF for Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

Available to Purchase
Elizabeth A. Mittendorf, Biao Lu, Michelle Melisko, Julie Price Hiller, Igor Bondarenko, Adrian Murray Brunt, Grybach Sergii, Katarina Petrakova, George E. Peoples
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4248–4254.
https://doi.org/10.1158/1078-0432.CCR-18-2867
Published: 15 July 2019
View articletitled, Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Open the PDF for Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial in another window
Journal Articles

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Available to Purchase
Linda C. Benavides, Jeremy D. Gates, Mark G. Carmichael, Ritesh Patel, Jarrod P. Holmes, Matthew T. Hueman, Elizabeth A. Mittendorf, Dianna Craig, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2895–2904.
https://doi.org/10.1158/1078-0432.CCR-08-1126
Published: 15 April 2009
View articletitled, The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Open the PDF for The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 in another window
Journal Articles

Overcoming Cancer Immune Tolerance and Escape

Available to Purchase
Guy T. Clifton, George E. Peoples
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 749–751.
https://doi.org/10.1158/1078-0432.CCR-08-2805
Published: 02 February 2009
View articletitled, Overcoming Cancer Immune Tolerance and Escape
Open the PDF for Overcoming Cancer Immune Tolerance and Escape in another window
Includes: Supplementary data
Journal Articles

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Available to Purchase
George E. Peoples, Jarrod P. Holmes, Matthew T. Hueman, Elizabeth A. Mittendorf, Asna Amin, Steven Khoo, Zia A. Dehqanzada, Jennifer M. Gurney, Michael M. Woll, Gayle B. Ryan, Catherine E. Storrer, Dianna Craig, Constantin G. Ioannides, Sathibalan Ponniah
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 797–803.
https://doi.org/10.1158/1078-0432.CCR-07-1448
Published: 01 February 2008
View articletitled, Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Open the PDF for Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 in another window
Journal Articles

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients

Available to Purchase
Zia A. Dehqanzada, Catherine E. Storrer, Matthew T. Hueman, Rebecca J. Foley, Katie A. Harris, Yusuf H. Jama, Tzu-Cheg Kao, Craig D. Shriver, Sathibalan Ponniah, George E. Peoples
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 478–486.
https://doi.org/10.1158/1078-0432.CCR-05-1425
Published: 20 January 2006
View articletitled, Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients
Open the PDF for Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients in another window
Journal Articles

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

Available to Purchase
Matthew T. Hueman, Zia A. Dehqanzada, Thomas E. Novak, Jennifer M. Gurney, Michael M. Woll, Gayle B. Ryan, Catherine E. Storrer, Christine Fisher, David G. McLeod, Constantine G. Ioannides, Sathibalan Ponniah, George E. Peoples
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (20): 7470–7479.
https://doi.org/10.1158/1078-0432.CCR-05-0235
Published: 20 October 2005
View articletitled, Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
Open the PDF for Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients in another window
Journal Articles

Clinical Studies of Vaccines Targeting Breast Cancer

Available to Purchase
Byung K. Ko, Kouichiro Kawano, James L. Murray, Mary L. Disis, Clay L. Efferson, Henry M. Kuerer, George E. Peoples, Constantin G. Ioannides
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3222–3234.
Published: 05 September 2003
View articletitled, Clinical Studies of Vaccines Targeting Breast Cancer
Open the PDF for Clinical Studies of Vaccines Targeting Breast Cancer in another window
Journal Articles

Peptide Priming of Cytolytic Activity to HER-2 Epitope 369–377 in Healthy Individuals

Available to Purchase
Brett W. Anderson, George E. Peoples, James L. Murray, Michael A. Gillogly, David M. Gershenson, Constantin G. Ioannides
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (11): 4192–4200.
Published: 01 November 2000
View articletitled, Peptide Priming of Cytolytic Activity to HER-2 Epitope 369–377 in Healthy Individuals
Open the PDF for Peptide Priming of Cytolytic Activity to HER-2 Epitope 369–377 in Healthy Individuals in another window
Journal Articles

Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers

Available to Purchase
George E. Peoples, Brett W. Anderson, Tom V. Lee, James L. Murray, Andrezj P. Kudelka, J. Taylor Wharton, Constantin G. Ioannides
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4214–4223.
Published: 01 December 1999
View articletitled, Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers
Open the PDF for Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers in another window